HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thacker, D. Articles by Rychik, J. Search for Related Content PubMed PubMed Citation Articles by Thacker, D. Articles by Rychik, J. Related Collections Congenital - cyanotic

---

Original Articles: Pediatric Cardiac

Use of Oral Budesonide in the Management of Protein-Losing Enteropathy After the Fontan Operation

^a Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
^b Division of Gastroenterology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Accepted for publication September 29, 2009.

^_* Address correspondence to Dr Rychik, Children's Hospital of Philadelphia, Single Ventricle Care and Research Program, 34th St and Civic Center Blvd, Philadelphia, PA 19104 (Email: rychik{at}email.chop.edu).

Background: Intestinal inflammation is a component of the pathophysiology of protein-losing enteropathy after the Fontan operation. Oral controlled-release budesonide is 90% metabolized at first pass through the liver, has high enteric anti-inflammatory activity and relatively low systemic effects, and may be an ideal agent for use in treating this disease.

Methods: Budesonide was administered to 9 patients (4 male) with protein-losing enteropathy after the Fontan operation. The median interval between the Fontan operation and diagnosis of protein-losing enteropathy was 4 years (range, 0.1 to 13.3). Prior interventional therapy included pulmonary artery stent (1), fenestration (3), pacemaker placement (3) and Fontan revision (2). Prior medical therapy included oral prednisone (5), heparin (4), sildenafil (2), infliximab (1), and octreotide (1), all without persistent success. The starting daily dose of budesonide was 9 mg for patients 4 years old or older, and 6 mg for patients less than 4 years of age.

Results: Mean serum albumin level 3 months before starting budesonide was 1.9 g/dL (range, 1 to 2.4 g/dL). Serum albumin level improved in all patients within 6 months of starting budesonide (mean 2.9 g/dL; range, 2.2 to 3.8 g/dL). Albumin levels of 3 g/dL or more were achieved in 8 of 9 patients within a median of 4.3 months (range, 2 to 25). Side effects included Cushingoid features and osteoporosis (3), infection requiring antibiotic treatment (5), and acne exacerbation (1). Weaning from high initial dose to a lower dose was possible with sustained effect; however, discontinuation of budesonide resulted in recurrence of hypoalbuminemia.

Conclusions: Oral budesonide is an effective therapy for treating protein-losing enteropathy after the Fontan operation. To maintain response, low-dose therapy must be continued.

This article has been cited by other articles:

				A. S. John, D. J. Driscoll, C. A. Warnes, S. D. Phillips, and F. Cetta The Use of Oral Budesonide in Adolescents and Adults With Protein-Losing Enteropathy After the Fontan Operation Ann. Thorac. Surg., October 1, 2011; 92(4): 1451 - 1456. [Abstract] [Full Text] [PDF]